How donanemab data address the coverage with evidence development questions
- PFCD
- Feb 1, 2024
- 1 min read
top of page
Search
Recent Posts
See AllDespite advances in disease-modifying treatments, significant barriers in the evaluation and clinical management of people with early Alzheimer's disease (AD) remain. These barriers have been document
bottom of page